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AT the University of Colorado Medical 
Center, 189 patients have been given kid-
ney homografts at a remote enough time 
to permit relatively long follow-up in the 
event of continued survival. On the basis 
of this experience, a reassessment will be 
attempted of the practical value of renal 
transplantation. In addition, the effect of 
various factors upon short and long-term 
survival will be examined including the or-
gan source, the quality of HL-A antigen 
matching, thymectomy before or after trans-
plantation, the addition of heterologous 
antilymphocyte globulin (ALG) to the im-
munosuppressive regimen, the develop-
ment of glomerulonephritis in the trans-
plants, and the occurrence of a significantly 
increased incidence of de novo malignancies 
in the recipients. 
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Case Material 
Temporal Subdivision of Experience 
The cases were divided on the basis of 
potentially important changes in either im-
munosuppressive management or donor se-
lection. 
Series 1. Between the autumn of 1962 
and March 1964, immunosuppressive ther-
apy was provided with azathioprine and 
prednisone.ol Except for the usual (though 
not invariable) precaution of assuring com-
patibility of red cell groups, donor selec-
tion was not guided by any pre-transplant 
immunologic evaluation. Actinomycin C 
was given to a few patients during epi-
sodes of rejection, and/or the homografts 
were locally irradiated. 
Series 2. Immunosuppression continued 
to be provided with azathioprine and pred-
nisone between October 1964 and April 
1966. However. an attempt was made to 
type lymphocyte antigens 83. 86 which be-
came known later as the HL-A system.46 
On thc basis of these serologic analyses, 
the best matched donor ",as selected from 
among those available. For the intrafamil-
--- '- -----_.---
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ial transplantations of Series 2, the number 
of potential donors for any given recipi-
ent was so small that there was no statisti-
cally significant improvement of the quality 
of matching over that which had been 
achieved in Series 1.83 In the non-related 
cases of Series 2, it was thought that the 
use of a donor pool of as many as 100 
volunteers would permit an appreciable 
upgrading of matching.83 In retrospect, the 
improvement was not particularly great, 
since the antigen measurements were so in-
complete by present-day standards. 
Series 3. In these patients, horse anti-
lymphocyte globulin (ALG) was added to 
the immunosuppressive agents azathioprine 
and prednisone. GO, 71 The ALG was given 
intramuscularly before or at the time of 
transplantation and in the average instance 
was continued for 4 months.70 Tissue typ-
ing was almost always performed prospec-
tively but failure to obtain a good tissue 
match was not considered to be a contra-
indication to operation. As a consequence, 
the quality of matching in Series 3 was not 
significantly dilIerent than in Series 1 and 
2. 
Subdivision According to Donor 
Consanguineous Homotransplantation. 
Excluding identical twins, there were 131 
consecutive intrafamilial transplantations. 
The primary renal homografts were do-
nated by 66 siblings, 55 parents, four un-
cles, four cousins, an aunt and a niece. The 
131 recipients underwent operations be-
tween November 1962 and February 1968. 
Consequently, potential follOW-lips of 2 to 
T1~ years arc now available. 
Non-related Homotransplantation. The 
first homografts for the othcr 58 recipients 
were ohtained from !lon-related donors. 
Thc operations \\'cre perfOlmcd betwcen 
February 1963 ami "larch 19G9, assuring 
potential follo\\'-ups oj one to more than 7 
\·ears. The minimum ohsen'atiol1 period for 
patients still alive was shorter for the non-
related transplantations (one year) than 
for the consanguineous cases ( 2 years). 
The shorter follow-up was accepted since 
the sample of non-related cases acquired 
late in our experience would otherwise 
have been too small to permit meaningful 
statistical comparisons with the earlier 
cases. The donors were living volunteers 
in 35 instances and in the other 23 they 
were recently deceased cadavers. Only ca-
daveric donors have been used in non-re-
lated cases since November 1965. 
Pathologic Material 
Kidney homograft samples have been ob-
tained from 163 of the 189 recipients as a 
result of open biopsy, transplant nephrec-
tomy or autopsy. In some cases more than 
one homograft was examined from a given 
recipient. All the tissues were examined by 
light microscopy. Sections were cut at both 
5 p. and 0.5 p.. The former were stained with 
hematoxylin and eosin, periodic acid Schiff 
( PAS) , Weigert's for elastic counterstained 
with hematoxylin and van Gieson, and 
methyl green pyronin. The 0.5 p. thick sec-
tions were stained with Azure 2. 
Electron microscopy was carried out on 
126 of the specimens. The tissue was fixed 
in Palade's buffered osmium tetroxide and 
embedded in Epon 812. Ultra-thin sections 
were stained with lead citrate and ex-
amined in a Philips 300 electron micro-
scope. 
From 96 of the homo grafts, samples of 
tissuc were frozen in liquid nitrogen and 
stored at -700 centrigrade until examined. 
Sections -4 1" thick w('re cut in a cryostat 
and stained with fluorescein conjugated 
.1Iltiscra." Thc fluorescent reagents used 
were all t iSl'ra made in ra bhits and goats to 
human IgG. rg~fI fihrinogen. C'lq and 
tilC; #IA globulin. Specificity of the anti-
,era ",as confirmed before a pplication to 
the tissue hy illll1111ll0-('!ectrophoresis and 
douhle eli/fusioll iu a~aroseK Specificity of 
tht' f1uorescl'llce \\'as established by block-
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RELATED HOMOGRAFTS 
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SERIES I . 46 VOLUNTEERS 
SERIES II (TYPED)- 25 VOLLNTEERS 
SERIES m (ALG)- 60 VOLUNTEERS 
FIG. 1. Life survival 
curves in the three se-
ries of intrafamilial renal 
homotransplantations de-
scribed in the text. In 
Series 3, the patients 
have been studied for at 
least 26 months. The fol-
low-ups in Series 2 and 
1 are for a minimum of 
4 and 6 years, respec-
tively. At the end of 
each survival curve a nu-
merator and denomina-
tor are given. The de-
nominator tells the num-
ber of living patients, and 
the numerator denotes 
the number of original 
homografts that are still 
functioning. 
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ing positive reactions with unconjugated 
antisera, by absorption of the labelled anti-
sera with specific antigens, and by the use 
of an anti-human serum albumin control. 
In so far as the method of tissue collec-
tion permitted, the presence or absence of 
the following features was determined in 
the homografts: (1) subendothelial glomeru-
lar capillary hasement membrane thicken-
ing; (:2) subepithelial glomerular capillary 
basemcnt memhrane thickening; (3) in-
creased ccllularity of the glomerular tufts; 
( -!) incrl'ascd amount of ml'sangial matrL"{; 
(.5) tubular atrophy; (6) intcrstitial fibro-
sis: (-;) mononuclcar cell infiltration of the 
interstitium; \ S) "hyalinc" ill the arteriolar 
wails: \ 9) thickcning of the intima of the 
interlobular arteries: (10) deposits of IgG, 
IgM. complement or fibrinogcn in the glo-
meruli, The lesions and deposits \\'ere 
graded ill scveritv from 0 to 4. 
I tl 139 cases. thc paticnts' o\\'n oiseascd 
kidne\'S \\"l'1'C examined and the findings 
\\'ere llltimatcl~D compared to those in 
the hOll1ografts. These specimens were all 
studied hy light microscopy and in a few 
instances I}\' immunofluorescence. 
Overall Mortality 
After Intrafamilial Transplantation 
According to Series. In Series 1, there 
was a heavy early mortality in that a third 
of the recipients (15/46) had died by the 
end of 7 months (Fig. 1). From this point 
on, the losses were encouragingly slight 
and only one patient each died in the SeC-
ond, third. fourth and sixth postoperative 
years. Today, 27 (58.7%) of the 46 recipi-
ents are still alivc after 6 to T~~ years (Fig. 
1). Twenty-five of these 27 patients are still 
living on the function of their original ho-
mografts. The two others received second 
transplants after 51; and 6 years. None of 
the 27 remaining paticnts is on dialysis. 
The acute mortality of Series 2 was re-
cluced to the extent that 84'/0 of the re-
cipients were alivc at 7 months. However, 
in spite of thesc first prospective attempts 
at histocompatibility typing, the results 
were slightly ,,'orse after 2, 3, and 4 years 
than ill Series 1 (Fig. 1). Of the 25 recipi-
ents, 13 ED::iOT~F still survive after 4 to 5% 
years, in each case with function of the 
original homograft. 
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TABLE 1. Results 'with Sibling Transplantation in Series 1-3 and in Combined Series 
Time in Months 
0 3 6 12 18 24 Current 
Series 1 23 16 15 14 (61%) 14 13 (57%) ·10 (43%) 
Series 2 9 9 9 7 (78%) 7 7 (78%) ··5 (56%) 
Series 3 34 33 32 32 (94%) 32 31 (91%) ···29 (85%) 
Total 
experience 66 58 56 53 (80%) 53 51 (77%) 44 (67%) 
• The 3 late deaths occurred after 30,37, and 64 months. The 10 current survivors have continuing function 
of the original homografts after 6 1/6-7 1/3 years . 
•• The 2 late deaths occurred after 25 and 33 months. The original homografts in the 5 survivors have func-
tioned for 4-5 1/2 years . 
••• The 2 late deaths were after 25 and 28 months. Twenty-eight of the 29 current survivors have function of 
the original homografts after 2 1/6-35/6 years. 
Follow-ups of more than 2 to almost 4 
years are available for the patients of Se-
ries 3 who received a 4-month course of 
ALe as well as indefinite azathioprine and 
prednisone. At 1 and 2 years, the patients 
(and kidneys) survived at rates of 92 and 
88%. There are 51 (85%) of the 60 re-
cipients still alive and in all but one, the 
original homografts are still providing life-
supporting function. The exceptional pa-
tient had a successful retransplantation 
using a cadaver kidney after 37(\ years. 
According to Donor Relation. The larg-
est experience with intrafamilial transplan-
tation was with sibling cases of which 
there were 66 (Table 1). Through Series 
1-3, there was a steady improvement in the 
one year, 2 year, and ultimate survival rate. 
Exactly two thirds (44/66) of the sibling 
recipients treated from 27 to 87 months 
ago are still alive and all but one of these 
patients have continuing function of their 
original homografts. 
The pooled survival in Series 1-3 after 
parent to offspring transplantation (Table 
2) was similar to that with siblings in that 
73% (40/55) of all recipients of parental 
kidneys are still alive from 26 to 90 months 
after their initial operation. Furthermore, 
38 of these 40 patients still have adequate 
function of the first grafts. In the two ex-
ceptional instances, retransplantation was 
carried out between 5 and 6 years. As with 
sibling transplantation. the best results 
were obtained in the ALG treated patients 
(Series 3). 
TADLE 1.. Results <"illl Parellt 10 lKffsprinK~ Tr<lIlSpl<lnlali'J/I ill Series 1-3 alld ill Cumbined Series 
Time in :\[onths 
0 3 6 12 18 U Current 
Series I 20 16 15 I-! (iO'';) I-! l-! EiMD~F '14 (iO";) 
Series 2 15 12 12 I) (60";,) () () «()()";) "S (53r-;) 
Series J 20 20 I () 19 (95";) I () IS (90";) ···IS E9M"~F 
Total 
experience ,::;S .. 8 -16 I~O li6'-;.) .. 1 -! I (i5";) 40 (73";) 
• The 1-! survivors have fo!low-ups of 6 I '6-; I '2 ,'cars. TWl'lve of these 1-! patients have continuing- function 
of their orig-inal kidneys, The other 1. had rctransplan tation at 5 1 '1. and 5 .=; '6 years. rl'spectivclv, 
•• Thc S surviving- patients arc -!-S I '2 ,'cars, ,\11 8 have continuing- iunction oi their oril-(inal hOl11og-rafts, 
••• Eleven oi the IS surviving- patients are 1. 1 2-35'6 ycars. The other 0 arc 2-2 1 '2 '·ears. All 18 survivors 
have continuin~ iunctiun of their ori~inal homografts. 
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TABLE 3. Results with Transplantation from Uncles, Cousins, an AlInt and a Niece* 
Time in Months 
0 3 6 12 18 24 Current 
Serijes 1 3 3 3 3 (100%) 3 3 (100%) 3 (100%) 
1 1 0 0 0 0 0 Ser1es 2 
Ser es 3 6 4 4 4 (67%) 4 4 (67%) 4 (67%) 
Total 
experience 10 8 7 7 7 7 7 (70%) 
• All 7 surviving patients have had function of their original definitive homografts after 2 1/3-6 1/6 years. 
Ten patients received homografts from 
relatives more distant than siblings or par-
ents. The pooled patient and kidney sur-
vival to date (Table 3) remains at 700/0 
(7/10) with follow-ups of 2Ya to 6y:! years. 
After Non-Related Transplantation 
In the unrelated Series 1, 2, and 3, re-
spectively, there were 18, 23, and 17 pa-
tients. At first (Series 1), all the donors 
were living volunteers. In Series 2, 6 ca-
daveric donors (260/0 of the 23 cases) were 
used and this source of organs was utilized 
exclusively for Series 3. 
At the end of 1 year, the survival in Se-
\ \. '-------. 
\ \ 
\ .\.\ 
\ ..... \ 
\ ' .. \ .. --~-K 
ries 1, 2, and 3 was 33%, 52%, and 82%. 
Subsequent to 1 year, the loss of lives and 
of homo grafts continued at a steady rate 
(Fig. 2). For example, the 41 patients in 
the pooled Series 1 and 2 now have poten-
tial follow-up intervals of 41f2 to more than 
7 years. Only eight (19.5%) of these 41 
early recipients are still alive and only 
five of them are being supported by their 
original transplants; the other three re-
quired retransplantation after 1, 21f2, and 3 
years. In Series 3, three deaths after 171h, 
25, and OT1~ months have reduced the sur-
vival from 82.3% at one year to the present 
level of 65%. 
NON·RELATED HOMOGRAFTS 
SERIES I' 18 VOLUNTEERS 
SERIES n (TYPEDI' 17 VOLUNTEERS 
AND 6 CADAVERS 
SERIES m (ALGI' 17 CADAVERS 
FIG. 2. Life survival 
curves in the three se-
ries of non-related renal 
homotransplantations de-
scribed in the text. The 
minimum follow-ups in 
Series 1. 2. and 3 are 6, 
4J,2, and 1 years. The 
significance of the nu-
merators and denomina-
tors at the end of each 
curve is the same as in 
Figure 1. 
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TIME OF DEATH 
0-3 Months 4-12 Months 13-24 MonthS over 24 Mont hs 
FIG. 3. The contribu-
tion of imperfect or 
failed renal function and 
of infections to the deaths 
of 79 patients. The shad-
ing of symbols indicates 
that infection either 
caused or was a major 
contributor to death. The 
squares indicate excellent 
premortem renal func-
tion. The triangles indi-
cate subnormal but life-
supporting premortem re-
nal function. The circles 
indicate that the homo-
grafts had failed. 
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Causes of Death 
Seventy-nine of the 189 patients have 
died, 40 after receipt of related kidneys 
and 39 after receiving non-related organs. 
Autopsies were performed in all but two. 
In reviewing the causes of the 79 deaths, 
a specific notation was made in every case 
about the roles of renal insufficiency and 
infection in the fatal outcome. Two asso-
ciations were obvious. First, 68 of the 79 
patients had less than normal (42 exam-
pies) or failed renal function (26 exam-
pies) in the interval before death (Fig. 3). 
Secondly, a major infectious complication 
was present in 58 (i3jo) of the cases (Fig. 
3). The most difficult therapeutic dilemma 
was posed by the co-existence of vari-
able degrees of renal impairment in con-
junction with sepsis. In this situation, life 
was threatened by reduced or failing func-
tion of the homograft and bv measures 
taken to prevent further dete~ioration or 
complete loss of the transplant. In 53 of 
the deaths ETM~F the combination of im-
perfect (or failed) homograft function and 
infection ",as present. ' 
The timing of death differed in the three 
periods of our experience. In Series L the 
mortality was hea\'i!v concentrated in the 
first 3 months (Fig, j) due in large part to 
a tendency to administer doses of azathio-
NON- NON-
RELATED RELATED RELATED 
6- 0 
• 0 • • • 
6-
• • 0 • 6-. .0 
0 .0 •• 
prine that caused bone marrow depression 
in the event of renal impairment. In Series 
2, this error was avoided. However, the 
mortality from infection was not prevented 
but only forestalled to the 4 to 12 month 
post-transplantation period (Fig. 3). With 
the more balanced form of immunosu~F-l 
pression used in Series 3, the deaths be-
came rather evenly distributed throughout 
the first 2 years. Moreover, only half of the 
patients in the last series had significant in-
fection at the time of death, compared to 
SOo/n and i6% in Series 1 and 2. 
The locations of the infections were 
highly variable but the most common were 
the lung (31 examples), the central ner-
vous system (five brain abscesses and three 
meningitides), the transplant wound (eight 
examples) and the peritoneal cavity (four 
examples). The infecting micro-organisms 
were frequently multiple hut it was usu-
ally possible to determine the dominant 
agent. Deaths in the first three months 
were clue mainly to well known hacteria 
such as Pseudomollas aCrtl<'inosa Esche-
", , 
richia coli and SfaphulococCtlS aUTeIlS 
(Table <1). ;\fter the early post-transplan-
tation months. nonbacterial (fungal, proto-
zoan. dral) infection played a major role 
I. Table -1). flet\\'l'en the 4th and 12th 
month after transplantation, Pneumocvstis 
carini accounted for five deaths and fu~gal 
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infections killed an additional five patients. 
After 4 months, four patients died from 
viral causes alone, three with viral hepa-
titis and the other with pan-intestinal 
varicella. Multi-organ cytomegalic inclu-
sion disease was found in many patients, 
often in association with pneumocystis 
carini. 
There were two deaths in the early post-
operative period from acute pancreatitis. 
Pulmonary emboli killed three patients 
(after 3, 181h and 28y:! months) and con-
tributed to the death of at least 10 others. 
Two recipients died of myocardial infarc-
tion O1~ and 4% years post-transplantation. 
As will be mentioned later, reticulum cell 
sarcoma accounted for two late deaths. Iso-
lated causes of mortality included suicide, 
inanition, stroke, and jejunal necrosis. 
Histocompatibility Determinations 
Tissue typing in these cases 13 was begun 
in the spring of 1964 with the serologic 
technic of lymphocyte antigen detection 80 
that has become widely used.sf Patients 
from our previous experience who had 
died by 1964 could not be studied but 
matching was carried out retrospectively 
upon the recipients still surviving and upon 
their donors. Subsequently, tissue typing 
was almost always carried out in advance 
of operation. At all times, the reagents used 
for typing were lymphocytotoxin-rich 1m-
man isoimmunc antisera obtained from per-
sons \\·ho had heen sensitized accidentally 
or deliherately to white cell antigens. 
The cytolysis of test lymphocvtes by such 
antisera indicated the presence of the same 
or a,imilar antigen as that which origi-
nall~D sl'lIsitized the serum donor. Failure 
of such a reaction implied the absence of 
the antil!;el1. When the lymphoc\'tes of both 
the dOllor and recipient rcacted the same 
to a giH'll antiserum. identitlf of that anti-
gen was said to be present. The ahsellce of 
;1Il antigen in a donor which was present in 
a recipient was defined as compatihilit". 
\ '"hen all antigen was found in thc donor 
TABLE 4. Pathogenic Organisms Involved in the 
lJeaths· of 79 Patients 
Bacterial: 
Staphylococcus aureus 
II emolytic Streptococcus 
Listeria monocytogenes 
Diplococcus pneumoniae 
Escliericltia coli 
Pseudomonas aeruginosa 
Klebsiella aerobacter 
Proteus mirabilis 
Paracolon species 
Viral: 
Hepatitis 
Cytomegalic inclusion dis. 
Varicella 
Protozoan: 
Pneumocystis carini. 
Fungal: 
As pergillus fumigaltts 
Candida a/Means and 
stelloidea 
Nocardia 
Histoplasmosis 
Cryptococcus 
Number of Patients 
Death with Infection at: 
over 
0-3 4-12 12 
mo. mo. mo. 
3 4 2 
4 0 0 
0 1 0 
1 0 0 
8 1 2 
12 8 5 
4 1 2 
3 0 0 
1 0 0 
0 1 2 
3 1 2 
0 0 1 
8 
2 3 2 
4 2 1 
0 2 0 
0 1 0 
0 0 1 
• Some patients died with 2-3 types of microorga-
nisms. For each patient the full spectrum of clinically 
significant microhiologic data has been entered into the 
lable. 
1:-'mphocytes but not on those of the recipi-
cnt, a mismatch existed. Identity of anti-
gens was preferable, compatibility was the 
next most satisfactory condition, and thc 
least desirable was an overt mismatch. 
The number of antiscra used for typing 
has been as largc as 200. Even when hu-
man typing was first performed it was ap-
preciated that many of the antisera in the 
total panel measured the same or similar 
h'mphocyte antigens. I3ctween 1963 and 
1968 ~ .•. ". 10. co. ·,e. 49,82.01,03 those antisera 
were classified by direct testing and b\' 
computer technics according to thcir speci-
ficity of action. In this wav, it eventually 
he'came possihle to definc human lympho-
cyte I IL-A antigens against which groups 
of antisera reacted. zo. Z3 
Since tissue t"l1ing was performed on our 
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TABLE 5. 57 Sibling Renal Homograjts 
Survival Time in :\10n ths 
:\fatch 
A 
B 
C 
D 
0 
17 
18 
16 
6 
3 
17 
17 
16 
6 
6 12 
16 16 
17 17 
16 14 
6 6 
24 
16 (94%) 
17 (94%) 
12 (75%) 
6 (100%) 
Current 
14 (82%)* 
14 (78%)** 
10 (63%)*** 
5 (83%)*"· 
The fate of 57 sibling renal homografts in relation to the histocompatibility matches. Loss of the homograft 
is considered the equivalent of death. The sibling cases of 1962-1964 have been included even though they were 
studied retrospectively since 14 of the 23 recipients of that era lived long enough to be typed. With x' analvsis the 
groups were not significantly different. • , 
* The late deaths occurred at 28 1/2 and 33 1/2 months . 
•• Late kidney loss or death after 25 1/2, 42 and 66 months . 
••• Late deaths after 25 1/2 and 37 1/2 months • 
•••• Late death is after 37 1/2 months. 
patients before as well as after the defini-
tion of HL-A groups, it was necessary to 
convert the year to year data into uniform 
terminology. This was done in December 
1969 and January 1970 by re-analyzing the 
results obtained with the original antisera 
in the early cases and by converting the 
findings into HL-A designations. At the 
least, it was possible to define eight anti-
genic groups and at the time of the most 
completely studied later cases, 11 groups 23 
could be identified. These groups will be 
referred to below as phenotypes. 
HL-A Phenotype Correlations 
With the definition of antigen groups, a 
histocompatibility grade (A-D) was given. 
An A match indicated identity of the mea-
sured donor and recipient HL-A antigen 
groups. With a B match, no incompatibili-
ties were present, but there were one or 
more examples of non-identity. C and D 
matches were progressively less satisfac-
tory with frank mismatches of one or more 
~mtigen groups. Because new HL-A groups 
were discovered and characterized through-
TABLE 6. 49 Parental Rellaillomografts 
Survival Time in :\{on1hs 
~[atch 0 3 6 12 24 Current 
:\ 5 5 5 3 3 ESMD~F 2 (40'7,)· 
B 19 16 16 16 16 EU4E~;-IF 15 (790;;,)·· 
C 22 22 21 20 .W E91"~F 18 EUOEI~KF·" 
0 3 3 3 3 2 (67';;,) 2 (67";.)···· 
The fate of -t9 parental renal homo~rafts in relation to thc histocompatibility matches. Loss of the hEFmo~rait 
is considercd the equivalent of death. The parental cascs of 1962-1964 have been included even thouJ,(h the,' were 
studied retrospectively since I-t of the 20 recipients of that era lived lon~ enou~h to be typed . 
.. In the late case, the maternal kidney has deteriorated so much that the patiellt beJ,(an to require occasional 
dialysis aftcr 6 I. '2 ,'cars, 
. • .. The late d~ath was caused by reticulum cell sarcoma aiter 29 112 months; renal function was subnormal 
with a creatinine clearance of 20-30 mi., min, 
.... The late homoJ,(rait losses occurrcd at 5 I '2 and .'i :; () \'ears; the patients werc both succcssfully retrans-
planted . 
•••• The 2 surviving patients have completely normal renal function after () J,'-t and -t 2,'3 ycars. 
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out the 6-year period of analysis, the basis 
for grading was more complete and conse-
quently more accurate at the end of the 
study than at the beginning. 
Survival. Mter intrafamilial transplanta-
tion, survival was not associated to a sta-
tistically significant degree with either com-
patibility or incompatibility. This conclu-
sion applied with sibling to sibling (Table 
5), and with parent to offspring combina-
tions (Table 6) as well as with transplan-
tation from more distant relatives. 
Histocompatibility typing was carried out 
prospectively in only 34 of the 58 unre-
lated cases and retrospectively in another 
five. The five retrospectively typed recipi-
ents were not included in this analysis 
since by the time they were studied they 
represented such a small number (28%) 
of patients remaining alive from the origi-
nal 18 of Series 1 that an unacceptable de-
gree of selection had already occurred. In 
the 34 prospectively typed cases there was 
TABLE 7. 34 Unrelated Renal Homograjts 
Survival Time in Months 
~ratch 0 3 6 12 Current 
B 8 5 5 5 (62.5%) 3 (37.5%)* 
C 17 15 12 12 (71%) 8 (47%)*· 
D 9 9 8 6 (67%) 4 (44%)*** 
The fate of 34 unrelated renal homografts in rela-
tion to the prospective histocompatibility matches as 
determined by serologic analysis. For this table, loss of 
the homograft is considered the equivalent of death. 
Since prospective matching was not carried out from 
1962 to March 1964, cases from that era have not been 
included. 
* The three current survivors are 14, 53, and 59 
months. The late deaths occurred at 171/2 and 44 1/2 
months. 
** The eight current survivors are 15, 15, 18, 24, 26, 
28, 57, and 59 months. The late deaths occurred at 
121/2,13,271/2, and 311/2 months. 
•• * The four current survivors are 12, 21, 23, and 
33 months. The late deaths occurred at 28 1/2 and 
481/2 months. 
not significant correlation of the match 
with survival (Table 7). 
Function and Immunosuppression. For 
TABLE 8. A ntigen ill atell l' emu r: idney Function and Steroid Doses 
Time Antigen), [a tch 
Post-Op 
Donor (Years) A B C D 
BUN Sibling 1 23.8 2-1.5 29.7 26.5 
mg./H)() ml. 2 23.2 21.4 30.6 29.6 
Parental 1 22.7 24.3 28.5 23.7 
2 23.6 24.6 33.4 20.5 
Creatinine Sibling 1 86.7 87.0 i3.3 88.1 
Clearance 2 93.4 87.9 i1.1 77.1 
ml./min. Parental 1 i2.6 69.1 69.5 65.2 
2 i3.3 iU 63.8 83.0 
Dailv Sibling 0.21 0.26 0.24 0.22 
Prednisone 2 0.16 0.21 0.25 0.23 
Dose Parental 0.24 0.24 0.30 0.30 (mg./Kld 2 0.20 n.21 0.25 0.16 
:'\0. of Sibling 16 Ii 14 () 
Patients 2 !() 16 12 (j 
Parental 3 16 20 .\ 
.! 3 15 20 2 
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these comparisons, A and B matches were 
pooled and compared with the combined 
C and D matches. In both the sibling and 
parental recipients the patients with A and 
B matched kidneys had slightly better 
function in that the a\'erage BUN's were 
lower and the creatinine clearances were 
higher at the end of the first and second 
postoperative years (Table 8). However, 
the differences were significant (p < 0.02) 
only in the sibling cases at 2 years. There 
was no correlation between the typing re-
sults and the average daily immunosuppres-
sion with prednisone and azathioprine at 
the first two annual follow-up times. Subtle 
late deterioration of function of the badly 
as opposed to the \\'ell matched kidneys 
was not e\'ident. 
There were 2.8 non-related C~lsesI five 
from Series 1, 9 from Series 2., and 1-1 from 
Series 3 in whieh good enough histocom-
patibilit\· typing was a \'ai/able to permit 
correlation of the match with the immuno-
suppressive treatment and homograft func-
tion. During the first postoperati\'e year, 
the seven patients who lived this long after 
receipt of 13 matched kidneys had higher 
a verage creatinine clearances (Fig. 4) and 
lower BUN's than patients with C and D 
matched kidneys. The prednisone (Fig. 4) 
and azathioprine doses were much the 
same in all three groups. Although sugges-
tive, the advantage of better renal func-
tion enjoyed in this small series by non-
related patients with n matched kidneys 
was not statistically significant. The credi-
bility of the observation was further weak-
('!led b}" the fact that the function of the 
C matched homografts was inferior to that 
of the organs from donors with D matches 
(Fig. 4). 
Pathology. There were 95 intrafamilial 
cases in which both phenotype data and 
tissue specimens wcre available; 50 were in 
the sibling, 39 in the parental, and Sl:oC 
in the more distantly related categories. 
Pathologic changes \wre asscssed in all the 
kidneys by light and electron microscopy. 
In many instances. immullofluorescent data 
was also available and \\":IS taken into ac-
vount. 
In the sibling kidneys ('xamineu at least 
1 year after transplantation. most of the 1:3 
kinds of immU!1()11uthologic lesions were 
Volume 17Z 
Number 3 
LONG-TERM SURVIVAL AFTER RENAL TRANSPLANTATION 447 
less frequent and less severe in the A 
matches than in the combined others 
(Table 9). The differences were significant 
(p < 0.05) in the amount of mesangial 
matrix in the glomeruli, tubular atrophy, 
interstitial fibrosis, mononuclear infiltration 
of the interstitium, "hyaline" in the arterial 
walls, thickening of the intima of the inter-
lobular arteries and in IgM deposition 
(Categories 4, 5, 6, 7, 8, 9, and immuno-
fluorescence, Table 9). The differences be-
tween the B, C, and D matched kidneys 
were not significant. 
In the parental kidneys there was no clear 
relationship between phenotype grades and 
the frequency and severity of the immuno-
pathologic lesions (Table 10). The same 
was true in homo grafts obtained from more 
distant relatives but these were too few in 
number to pennit meaningful correlation 
of the pathologic changes with the antigen 
match. 
In addition to the foregoing intrafamilial 
cases, there were 29 nonrelated transplan-
tations in which homograft samples were 
obtained from a few days to more than 4 
years after operation. In eight instances the 
homografts were B matched, in 12 others 
there was a C match and in the other nine 
the match was designated D. Pretransplan-
tation thymectomy had been carried out in 
three, five, and one of the B, C, and D-
matched recipients, respectively. There was 
some inequality of immunosuppression in 
the groups being compared in that more of 
the patients with C and D matches re-
ceived treatment with ALe since they fell 
into the Series 3. For the purposes of the 
analysis the influence of both thymectomy 
and ALG therapy were not given weight. 
The average damage to the B, C, and D 
grafts was approximately the same (Table 
11). 
HL-A Genotype Correlations 
From family studies, it became evident 
that the detenninants of the HL-A antigens 
were on one chromosome 3.',7,10,11,62,93 
and were probably localized to two sub-
loci.8, 23. 29, 62 These antigens were shown 
to be transmitted in combinations from 
generation to generation in accordance 
with classical Mendelian law.7 • 11. 2D As a 
consequence, it was possible within fami-
lies to use the pattern of the HL-A pheno-
types as a means of establishing geno-
TABLE 9. Sibling Donors 
Pathologic Lesions VS. Tissue Match 
.\{ean Scorc' for Each of 9 Types of Histopathologic Abnormalityt and for Four 
Tissue ~EFK of Kinds of Glomerular Deposit 
'\fatch Cases 2 3 -t 5 6 i 8 9 IgG f~M C' Fib. 
,\ l-t 0.88 0.58 0.22 0.36 0.45 0.64 0.50 0.86 0.29 0.67 0.58 0.67 0.17 
B 16 1.38 0.63 0.50 1.13 1.50 1.56 n.88 1.63 1.31 11.31 1.08 0.54 lUI 
( . 12 1.58 0.50 0')2 0.67 1.-t2 1.'>2 1.58 1.25 2.08 1.78 1.55 1.22 1.11 
D 5 1.20 IHO 0.40 1.60 2.00 2.20 1.40 1.80 1.60 0.25 1.25 1.00 0.50 
•• P values 0.1 0.5 0.1 0.03 0.01 lWO! 0.01 0.05 0.001 0.6 0.05 0.6 0.1 
'See text ior details oi hoth histopatholo/.:ic ~radin~ systems and for discussion of the timin~ of tissue sample 
procuremen t. 
t Type I = Subendothelial ~fomerular capillary hasement memhrane thickcninl!. 2 = Subepithelial/.:lomcrular 
capillar~D basement membrane thickeninK~K 3 = Increased ccllularit\' of ~fomerular lUits. -t = Increased amount of 
mesangial matrix. 5 = Tubular atroph~·K () = Interstitial tibrosis.· i = \[ononuclear cell intiltration oj the inter-
stitium. S = "1f~Daline" in arteriolar walls. <) = Thickening of intima of interlobular arteries. IgG = immuno/.:iobu-
lin G; f~~r = immunoglobulin .\[; C' = complemcnt: Fib. = tibrinogen . 
•• Comparison is between A and combined ll-D kidne\'s. 
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TABLE 10. Parental Donors 
Pathologic Lesions vs. Tissue Match 
Mean Score for Each of 9 Types of Histopathologic Abnormality and for Four 
Tissue ~oK of Kinds of Glomerular Deposit· 
Match Ca.ses 2 3 oJ, 5 
A 4 0.75 0 0.75 0.75 Li5 
B 13 1.23 0.15 0.62 0.54 1.23 
C 16 1.13 0.13 0.50 0.50 1.44 
D 3 tOO 0 1.33 0.67 1.33 
• Footnotes same as in Table 9. 
types," 10, 29 and to then correlate the geno-
type designations with the fate of skin or 
renal homografts.3, 5, 6, 82, 93 
In parent to offspring transplantations, 
half of the recipient HL-A alleles (one 
haplotype) are by definition from the do-
nor whereas the other haplotype is in es-
sence unrelated in respect to the donor. 
With transplantation between siblings, it 
is theoretically possible 3, 6. 11 for brothers 
and/or sisters to inherit two identical HL-A 
haplotypes from their parents at about a 
25% incidence, to have a single haplotype 
in common in about half the cases, and to 
share neither haplotype in the other fourth. 
In 51 of the 66 sibling transplantations 
of the present study, an attempt was made 
to convert the HL-A phenotypes into geno-
types. The information about antigens was 
programmed for computer evaluation by 
Dr. M. R. Mickey to determine in which 
cases the donor and recipient had double 
haplotype identity at a probability of 0.7 
or greater. The probability figures de-
6 7 8 9 IgG IgM C' Fib. 
LiS 1.25 1.00 2.50 1.00 LSO 1.00 0 
1.31 0.92 0.85 1.09 0.31 0.85 0.31 0.31 
LS6 LSO 0.88 1.50 0.72 1.44 0.64 0.43 
1.67 1.67 1.00 1.00 0 0 0 0 
pended upon several factors including the 
results and completeness of the antigen 
analysis as well as the frequency distribu-
tion of the different measured antigens in 
the non-related population, The outcome 
in 16 HL-A identical sibling cases was 
compared to that observed with the other 
35 sibling transplantations for which dou-
ble haplotype identity had not been estab-
lished. 
Survival. At 2 years, the patient (and 
kidney) survival in the double haplotype 
identical cases was 94% as compared to 
S9% in the less favorably matched group 
(Table 12). The advantage of double hap-
lotype identity was accentuated after 2 
years until at the present time the survival 
is still 88 % versus 7470 for the pooled re-
maining cases (Table 12). However, the 
better results in the double haplotype 
identical cases were not statistically sig-
nificant. 
Function and Immunosuppression. At 
1 and 2 years. 15 recipients with double 
TABLE 11. ('I/re/a/cd J)OIlOTS 
Pathologic Ll'sions \'5. Tissue :'.Iatch 
:'.Iean Score lor Each of I) Types 01 Histopatholodc .\i.llormality alld for four 
Tissue "-0. of Kinds oi CI,)merular I h-pnsits' 
:-'Iatch Cases 2 .\ -+ .- II S I) kG k:'.[ (" Fib. 
B 6 1.81 ll . .l.l lUll 100 1.33 150 O.s3 1.33 1.50 11.110 I.W osO O.W 
C S 1.88 IUS 1.50 1.38 2. t3 2. \3 LiS l.rd 2.25 I)(l!) 1.20 1.00 o.()() 
0 S 2.13 (U8 1.00 Us 17S 1.113 2.0 150 1.113 10 IJlI 133 n.17 
• footnotes same as in TallIe Y. 
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TABLE 12. 51 Sibling Renalllomografts 
Survival Time in Months 
0 3 6 12 24 Current 
Two haplotypes 
identical (P ~ 0.7) 16 16 15 15 15 (94%) 14 (88%)* 
All others 35 35 35 33 31 (89%) 26 (74%)** 
The fate of 51 sibling renal homografts in relation to haplotype. Loss of the homograft is considered the equiva-
len t of death. 
* The late death occurred at 33 1/2 months from Torula meningitis. 
** Late kidney loss or death after 25 1/2,31,37,42, and 66 months. 
haplotype-identical donors had somewhat 
better average renal function and were re-
ceiving smaller maintenance doses of pred-
nisone than 30 other sibling recipients with-
out double haplotype identity who also 
survived for at least 2 years (Table 13). 
However, the differences between the two 
groups were not statistically significant ex-
cept for the 1 year BUN (p < 0.05). 
Pathology. Homograft tissue became 
available 1 year or longer after operation 
from 13 of the 16 patients with double hap-
lotype identity. The abnormalities in the 
transplanted organs were distinctly less 
than in 28 other sibling cases in which the 
double haplotype identity could not be es-
tablished. The advantage enjoyed was sta-
tistically significant for 10 of the 13 kinds 
of tabulated abnormalities (Table 14). In 
particular, the amount of subendothelial 
thickening of the glomerular capillary base-
ment membranes, the amount of mesangial 
matrix, the degree of interstitial fibrosis, 
the number of mononuclear cells infiltrat-
ing the interstitium, and the severity of the 
arteriolar and arterial obliterative changes 
were much less in the double haplotype 
siblings. 
Homograft Glomerulonephritis 
Homografts were studied after residence 
for from a few days to more than 5 years 
in 163 of the 189 recipients. All of the 
specimens were submitted to light micros-
copy, 96 were studied with immunofluores-
cence, and 126 were examined by electron 
microscopy. 
Definition of Terms 
Definite Glomerulonephritis. A diagno-
sis of glomerulonephritis was made if, by 
light microscopy, over 50 per cent of the 
glomeruli showed one or more of the fol-
lowing features: (1) focal or diffuse hyper-
cellularity of the tufts; and (2) focal or 
TABLE 13. Siblillg rrallsplalltation 
Haplotype Versus Kidney Function and Steroid Dose 
T\\"o haplot.\·pe 
idcntit~· ! p c:- .Oil 
Other siblin~s 
Time 
Post-tx 
!Years) 
2 
2 
'\0. Patients 
15 
15 
30 
30 
BeN 
il11;:./IOO ml.) 
20.8 
20.-l 
26.1 
24.5 
eer 
(ml./min.) 
S-l.9 
t).\A 
S4.9 
1:'3.9 
Pred 
img./K;:.) 
.23 
.Ii 
.23 
.23 
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generalized thickening of the capillary 
basement membranes. These two basic 
pathologic changes might, or might not, be 
accompanied by epithelial cell crescents, 
by a focal or generalized increase in the 
amount of mesangial matrix, and by the 
presence of deposits of immunoglobulins 
and complement on the glomerular capil-
lary wall. 
Possible Glomerulonephritis. Glomeru-
lonephritis was considered a possibility if 
the glomeruli appeared nonnal on light 
microscopy but: ( 1) electron microscopy 
revealed an excess of predominantly non-
cellular material on either aspect of the 
glomerular capillary basement membranes: 
the material could be of any degree of 
electron density; andlor (2) immunofluo-
rescence demonstrated deposits of immu-
noglobulins and complement on the glo-
merular capillary walls. The deposits could 
be in a granular, linear or mixed pattern. 
Incidence of Glomerulonephritis 
Definite Glomerulonephritis. By light 
microscopy, 56 of the 163 homografts were 
diagnosed as having glomerulonephritis for 
an uncorrected incidence of 34.4%. In the 
kidneys examined at least 1 year after 
transplantation this diagnosis was made in 
50 of 105 instances giving a corrected inci-
dence of 47.6% (Table 15). 
Possible Glomerulonephritis. An addi-
tional 25 of the 163 kidneys (15.3%) had 
ultrastructural or immunopathologic glo-
merular lesions that were compatible with 
glomerulonephritis. Twenty-three of these 
specimens were among the 105 kidneys ex-
amined a year or more after transplanta-
tion, for a corrected incidence of 21.9% 
(Table 15). 
Non-related Versus Related Cases. 
Only corrected incidences will he given 
since early deaths occurred so much more 
frequentl~D in the non-related recipients. 
Amongst the 105 grafts examined a \-ear or 
more after transplantation 21 were from 
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TABLE 15. Glomerulonephritis* in 105 Renal Homografts One Year or More After 
Transplantation, and Correiations with Original Disease 
No Evidence Definite Possible 
No. of Glomerulo- Glomerulo- Glomerulo-
Original Disease Cases nephritis nephritis nephritis 
Related Glomerulonephritis 64 18 30 16 
donors Pyelonephritis 9 3 2 4 
Other Renal Disease 3 2 0 1 
Unknown 8 4 2 2 
Total 84 27 (32.1%) 34 (40.5%) 23 (27.4%) 
Unrelated Glomerulonephritis 11 2 9 0 
donors Pyelonephritis 3 1 2 0 
Other Renal Disease 2 2 0 0 
Unknown 5 0 5 0 
Total 21 5 (23.8%) 16 (76.2%) 0 
Total Glomerulonephritis 75 20 (26.7%) 39 (52.0%) 16 (21.3%) 
cases Pyelonephritis 12 4 (33.3%) 4 (33.3%) 4 (33.3%) 
Other Renal Disease" 5 4 (80%) 0 1 (20%) 
Unknown 13 4 (30.8%) 7 (53.8%) 2 (15.4%) 
Total 105 32 (30.5%) 50 (47.6%) 23 (21.9%) 
* See text for criteria of diagnosis. 
** Three polycystic, one medullary cystic disease, one surgical accident and loss of single kidney. 
non-related and 84 were from intrafamilial 
donors. 
Sixteen of the 21 non-related kidneys 
(76.2%) had stigmata of glomerulonephri-
tis that were evident on light microscopy 
(Table 15). In contrast, this definite diag-
nosis could be made in only 34 of the 84 
related kidneys (40.5%). The difference 
was found to be significant (2 X 2 contin-
gency table: chP = 8.50; P < 0.01). 
However, more subtle glomerular lesions 
detectable only by electron microscopy or 
immunofluorescence were found in a fur-
ther 23 related kidneys but not in any ad-
ditional non-related organs (Table 15). If 
the definite and possible diagnoses of glo-
merulonephritis were pooled. the incidence 
for the related group became STK9~~I a fig-
ure that was not significantly different than 
the 76.2 ~Dc> in the non-related grafts. 
Relationship to Original Disease 
The patients' own diseased kidneys were 
examined histopathologicallv in 159 of the 
189 cases of the present report and the 
findings were eventually compared to those 
in the homografts. In 105 of these cases 
the homograft tissue was obtained a year 
or more after transplantation; the results 
in this special collection are summarized in 
Table 15. 
When the original disease had been 
clearly glomerulonephritis (75 patients), a 
diagnosis of glomerulonephritis in the ho-
mograft was either definitely made ( 39 
grafts) or else considered a possibility (16 
grafts) for an overall incidence of 73.3% 
(Tables 15 and 16). The native kidneys in 
these cases were found to have various 
morphologic varieties (membranous, pro-
liferative, lobular. etc.) of glomerulone-
phritis. Features of the glomerulonephritis 
in 23 of these 55 organs were either identi-
calor similar to those found in the host's 
own kidneys. However, the majority of the 
affected grafts (32 of 55) had glomerulo-
nephritis changes that were not a faithful 
or nearly faithful anatomic recapitulation 
of the original disease. 
When pyelonephritis or other non-glo-
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TABLE 16. Incidence oj "Transmission Glomerulonephritis" in Renal Homografts Examined 
One Year or Longer ajter Transplantation to Patients Whose Original 
Disease was Glomerulonephritis 
Related 
Unrelated 
Total 
No. of 
Cases 
64 
11 
75 
Definite or Possible 
Glomerulonephritis 
in Homograft 
46/64 (71.9%) 
9/11 (81.8%) 
55/75 (73.3%) 
merulonephritic disorders were thought to 
have been the cause of the patients' renal 
failure (17 recipients), nine of the trans-
planted kidneys (53%) examined 1 year 
or more later had findings either diagnostic 
of (four grafts) or compatible with (five 
grafts) glomerulonephritis (Table 15). 
The pathologic differentiation of glomeru-
lonephritis from pyelonephritis is some-
times very difficult in end-stage kidney dis-
ease. Consequently, a small group of 13 
recipients was of special interest because 
the original renal disease was neither glo-
merulonephritis nor pyelonephritis and it 
was almost certainly not of immunologic 
etiology. Six of the patients had suffered 
from polycystic disease and two from ob-
structive uropathy. In two more, an onl~r 
kidney had been accidentally removed. The 
other three diagnoses were congenital me-
dullary cystic disease, cystinosis and oxalo-
sis. Five of these recipients died within the 
first 2 postoperative months. At autopsy, 
one of the five transplants had definite 
signs of glomerulonephritis. In this case, 
the recipient's original renal failure was 
due to polycystic disease. The eight other 
homografts were studied more than :2 
months after operation. There was glo-
merulonephritis after 71 ~ months in the 
kidney transplanted for the treatment of 
oxalosis. L'ltrastructural lesions compatible 
with glomerulonephritis were present after 
:2 years in the graft of another patient 
whose original diagnosis was polycystic 
disease. 
Glomerulonephritic Changes in Homograft 
Iden tical to 
Host's Own 
Kidneys 
8/64 (12.5%) 
3/11 (27.3%) 
11/75 (14.7%) 
Similar to 
Host's Own 
Kidneys 
10/64 (15.6%) 
2/11 (18.2%) 
12/75 (16.0%) 
Different than 
Host's Own 
Kidneys 
28/64 (43.8%) 
4/11 (36.4%) 
32/75 (42.7%) 
Relation of Glomerulonephritis to Histo-
compatibility 
Except for the sibling cases there was 
not a relationship between the quality of 
histocompatibility match and freedom from 
glomerulonephritis in the kidneys examined 
at least 1 year after transplantation. In the 
siblings the glomerular lesions tended to be 
somewhat less frequent and less severe in 
the A-matched kidneys. An advantage of 
good sibling matching was evident to a 
significant degree in the double haplotype 
identity cases. This fact can be appreciated 
by reviewing those immunopathologic fea-
tures in Table 14 that define the presence 
or absence of glomerulonephritis, namely 
the lesion categories 1-3 as well as the im-
munofluorescent studies. 
Chronic Adverse Effects of Homograft 
Glomerulonephritis 
There were 34 kidneys from related do-
nors that were aillicted with definite histo-
pathologic signs of glomerulonephritis but 
which supported life for at least 1 post-
operative year. Between 12 and 24 months, 
three of these kidneys became totally non-
functionaL two of the three patients died 
and the third n>(luired dialysis. The func-
tion of six more of the organs (:!O%) Je-
teriorated in terms of BUN and creatinine 
dearanee. III contrast. only one of the :28 
illtrafamilial rccipients with nonglomerulo-
nephritic transplants dicd during the same 
interv;! I. and functional deterioration oc-
curred ill only one other instance 1PKT~rFK 
Volume 172 
Number 3 LONG-TERM SURVIVAL AFTER RENAL TRANSPLANTATION 453 
In the non-related cases, the rate of death 
or homograft deterioration was also higher 
( 63%) with glomerulonephritis than with-
out (40%). 
At 2 years, the diagnosis of definite ho-
mograft glomerulonephritis in 44 recipients 
was associated with significantly poorer re-
nal function than in 51 patients whose kid-
neys were without such distinct histopatho-
logic changes (Table 17); the correlation 
applied in both related and unrelated cases. 
The incidence of proteinuria in the patients 
with definite glomerulonephritis was 50% 
(22/44) compared to 2% (2/.51) in the 
other cases (Table 17) in which glomeru-
lar lesions were either absent (no glomeru-
lonephritis) or detectable only with ultra-
structural or immunofluorescent study (pos-
sible glomerulonephritis) (Table 17). 
Immunosuppression Versus 
Histopathology 
For this analysis, the biopsy, autopsy and 
homograft nephrectomy specimens obtained 
1 year or more after transplantation in Se-
ries 1 and 2 were pooled. These patients 
were treated with azathioprine and pred-
nisone. Comparisons were made with the 
specimens of Series 3 taken from patients 
who were also given ALG. Only the re-
lated cases were considered because the 
number of unrelated cases in Series 3 was 
too small to permit useful statistical analy-
sis. Even in the related cases, valid sta-
tistical evaluations were difficult because 
the pooled Series 1 and 2 represented a 
more selective collection. In Series 1 and 2, 
the mortality before the end of the first 
year was in excess of 30%, whereas in 
the consecutive ALG-treated patients more 
than 90% potentially qualified for inclu-
sion in the study by virtue of their survival 
for the requisite interval. 
In the homografts examined, there was 
not a striking difference in the kidneys of 
Series 1 and 2 as compared to those in Se-
ries 3 (Table 18). There may have been 
more IgM in the kidneys of Series 1 and 2, 
but several other kinds of findings were 
somewhat prominent in Series 3, including 
IgG and fibrinogen (Table 18). 
Hypertension and Vascular Lesions 
Acute arterial hypertension is a very 
common but highly reversible manifesta-
tion of acute homograft rejection.·4 Chronic 
hypertension is a less well recognized com-
plication. The incidence of this late com-
plication was evaluated in 105 patients who 
lived for at least 1 year and whose homo-
grafts became available for histopathologic 
study. Related and unrelated cases were 
considered together. A blood pressure score 
was assigned on a 0-4 scale in which 0 
represented a normotensive state without 
any necessity for medication, four indi-
cated uncontrolled hypertension in spite of 
TABLE 1 i. Renal F,mctioll alld Pro/eillum .l/ter r",o Years I's. Groll/emltlr Pathology 
:-\0. of BUN Ccr 
Patholol!Y Patients E:yr~K/llEF 011.)" E:y[yK/~linKF" Proteinuria •• 
Definite 
;;Iomcruloncphritis·" 44 34.5 ± 2.5 61.5 ± 4.8 22/44 (50';) 
Possiblc 
e;lomerulonephritis 23 22.3 ± 2,4 is.i ± 5.2 1/23 (44';) 
:-\0 
;(Iomerulonephritis 2S 19.6 ± 1.1 90.2 ± 5.; 1128 (3.0' ;) 
• Oc\'iations arc standard errors of t he mean . 
•• Fraction oi patients hadnl! more than 300 m"./ O~ hrs . 
••• Dillerences in the renal functions and in proteinuria were all si:;niticant (p < 0.05) when compared to either 
oi the other groups at each time period. 
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TABLE 18. HistopatllOlogy of ALG Cases Vs. Others 
Mean Score for Each of 9 Types of Histopathologic Abnormality and for Four 
Kinds of Glomerular Deposit· 
Series 
No. of 
Cases 2 3 5 6 7 8 9 IgG IgM C' Fib 
1 and 2 
3 
48 
36 
1.31 0.29 0.56 0.88 1.13 lAO 1.02 0.88 1.25 0.51 1.28 0.69 0.29 
1.22 0.44 0.58 0.97 1.39 1.53 1.25 1.61 1.31 0.97 0.94 0.68 0.53 
* Footnotes same as in Table 9. 
multiple drugs in large doses, and 1-3 rep-
resented intennediate pennutations. 
Only a third of the patients had com-
pletely nonnal blood pressures (Table 19), 
although in most of the others satisfactory 
control was obtained with drug adminis-
tration. When the histopathologic findings 
in the homografts of these 105 recipients 
were plotted against the hypertension 
scores, good correlations were found be-
tween raised blood pressure and almost all 
of the kinds of lesions, especially the pres-
ence of thickening of the intima of the in-
terlobular arteries, tubular atrophy, and in-
terstitial fibrosis in the homograft (Table 
19). 
Thymectomy 
Before Transplantation 
In eight of the first renal homograft re-
cipients at the University of Colorado, thy-
mectomy was carried out prior to trans-
plantationK·~ The unusually untroubled 
early and late courses of some of these pa-
tients was alluded to in past reports,G4. 1~ 
and attention drawn to the possible con-
tributing role of the thymectomies. In or-
der to clarify this issue, a prospective study 
of the effect of thymectomy was carried 
out in an additional group of patients 
treated between October 1964 and June 
1966. These cases belonged to Series 2 ex-
cept for the first four cases of Series 3. 
Transthoracic thymectomy was perfonned 
in 24 of the recipients; the other 22 served 
as controls. A similar spectrum of donor-
recipient lymphocyte antigen compatibility 
was present in both the test and control 
series. 
The results of the random thymectomy 
investigation have been fully documented 
in a recent report 73 and will only be sum-
marized here. In both the related and non-
related cases and with follow-up intervals 
of 4 to R~~ years, there has not been a sig-
nificant advantage of thymectomy in tenns 
of homograft survival (Fig. 5), reduced 
drug dosages or quality of renal function. 
However, pathologic studies with light and 
electron microscopy and with immunofluo-
rescence revealed that the homografts in 
the 24 thymectomized patients had not suf-
TARLE It). Pathologic Lesions t's. flypertensioll 
Grade of Hypertension :\[ean Score for Each of t) Types of Histopathologic :\bnormality· 
1 Year after Xo. of 
Transplantation" Cases 2 3 4 5 6 8 9 
0 35 1.00 (UO (lAo (l.60 (l()4 1.09 0.94 n.74 0.86 
2S 1.39 0.32 0.0\ 0.S9 132 1.54 I.Oi l.IH 1.43 
2 23 l.i0 (1.30 O.i4 1.35 1.83 Ul7 1.48 I.S3 lA3 
.l 15 2.07 f).SO 1.13 1.;3 2.00 2.00 lAO I.Hi 2AO 
4 4 1. 7.'i f) 0.i5 1.00 2.50 2.50 2.25 1. is 3.25 
Correlation coelncient r 0.S5 (UO (J.iO 0.59 n.99 0.99 n.t) I 0.S6 n.95 
• See text for details of hypertension grading system. Other footnotes same as Table 9. 
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., 
, FIG. 5. Life survival 
curves in a series of 46 
patients of whom 24 
were submitted to thy-
mectomy prior to trans-
plantation. Note that thy-
mectomy had no statisti-
cally Significant influence 
upon survival after trans-
plantation from either re-
lated or non-related do-
nors. The figw-es at the 
end of each survival 
curve indicate the num-
ber of recipients at the 
outset of the study. 
<.? ••••••••••••• \ 
\ 
...............••. z .7 :> 
'> 6 cr:' 
:::J 
.... ---... --~ \ (15) 
en .5 
z 
0.4 
f= 
••••••• obiAqba~ 
" (14) 
\ klk-obiAqba~ (10) ~ .3 
cr: 
lL... 
- THYMECTOMY 
~ 00 0 0 000 0 00 OO!!-O !eeeMf~o""" 
I 
I 
.2 --- NON-THYMECTOMY I I 
.1 
I 
000 (7) 
l~~----------------------~~~----~--~------4 8 ~ ~ W M ~ ~  ~ «  ~ ~ 
fered as much long-term damage as in the 
22 non-thymectomized controls.T5 The kid-
neys in the thymectomy series had less se-
vere cellular infiltration and fewer lesions 
of the vascular, glomerular and fibrotic va-
rieties described elsewhere in this report. 
Late Thymectomy 
Five years ago a separate group of 9 pa-
tients was described in which thymectomy 
was carried out from BY:? to 17 months after 
renal homotransplantation in the hope that 
the requisite level of maintenance immuno-
suppression could thereby be reduced.13 
There had been complications in the post-
operative courses of these recipients. Five 
had developed late rejection, two had ster-
oid induced cataracts, one had a uretero-
vesical stricture requiring an extensive re-
parative operation and one had become 
jaundiced. 
At the time these cases were reported, 
there was no evidence that the delayed 
thymectomy had had any influence upon 
the subsequent course. Five years later the 
same is still true. Within the group of nine 
patients, there were seven recipients of 
familial kidneys (five maternaL two sib-
ling); two of these seven homografts failed 
TIME IN MONTHS 
after two and six years. The other two pa-
tients had received kidneys from non-re-
lated living volunteers. The transplants be-
came unable to support life after O~ and 
4Y:J years, respectively. The first patient 
was successfully retransplanted and is still 
alive, but the second one died of a per-
forated sigmoid diverticulitis about two 
months after retransplantation. 
The Risk of Malignancy 
It was predicted by several authors 18, 5!1, 04 
that chronically surviving organ transplant 
recipient would have an increased risk 
from de novo malignancy but the first for-
mal reports of this complication were not 
made until 1968.°0 - G7 Since then, it has be-
come obvious 15. 00-5". 00 that a significant 
risk of neoplasia must be accepted as part 
of the price for success after renal trans-
plantation. The point can be illustrated 
from our personal experience as well as by 
summarizing obervations made in other 
centers and compiled in Denver through 
an informal tumor registry. 
Colorado Experience 
Among the 189 recipients of the pres-
ent report, there have been 10 (5.3j;) 
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who have developed primary malignancies 
(Table 20), either of epithelial (seven ex-
amples) or mesenchymal origin (three ex-
amples ). In no instance was there any ob-
jective evidence of a neoplasm prior to 
transplantation. Afterwards, the diagnosis 
of tumor was made following intervals of 
5* to i5 months. The donors of the 10 
homografts were living volunteers who are 
still alive and in good health from 2Jf2 to 
7 years later. None has ever had a malig-
nancy, either before or after nephrectomy. 
The true incidence of neoplasia was actu-
ally higher than 5.3%. Forty of the 189 pa-
tients died from a variety of non-neoplastic 
complications before the end of the fourth 
postoperative month. At autopsy, the only 
tumor in these 40 recipients was a papil-
lary adenocarcinoma in a patient who died 
2 days post-transplantation of a splenic ar-
terial hemorrhage. It was in the remaining 
149 recipients who lived beyond the fourth 
postoperative month in whom the 10 neo-
plasms developed, for a partially corrected 
incidence of almost 7%. The rate of tumor 
development in these young patients (5 to 
49 years, average 32) compares with the 
yearly risk of about 0.06% in the general 
population at a comparable age range. '1l 
There were several conditions that were 
common to all 10 recipients; the continu-
ous presence of a renal homograft postop-
erative immunosuppressive treatment with 
azathioprine and prednisone, and splenec-
tomy. Factors which were present in some 
but not all patients included thymectomy 
before transplantation ( four) or afterwards 
(one), trcatment with actinomycin C (four), 
local homograft irradiation (nve), or intra-
muscular ALG (three l. It was of particu-
lar interest to note the incidence of ma-
fignanc~D in patients gi\'cn azathioprine and 
prednisone (Series 1 and :2) as opposed to 
thc incidence ",hen :\LG was used as well 
(Series 3). The number of patients at risk 
for 1 and :2 years ill Series 3 was slightlv 
greater than in the combined Series 1 and 
2. During this time and eyen between :2 
and 3 post-transplantation years the inci-
dence of malignancy was not proportion-
ately higher in patients given triple agent 
therapy. 
The behavior of the malignancies dif-
fered according to their origin (Table 20). 
Those rising from epithelium (skin and 
cervix) appeared from 32 to 75 months 
after transplantation and in patients whose 
average age was 38 years. The tumors were 
relatively slow growing and in every case 
they were apparently controlled with ex-
cision by conventional surgical technics. 
In contrast, the three lymphomas ap-
peared earlier (after 5%, 7 and 30 months) 
and in patients who averaged only 19 years 
of age. In two instances, the neoplasms 
were fatal within a short time. The third 
patient was saved 111 by applying radiother-
apy to the space occupying lesion in the 
brain and by drastically reducing the main-
tenance doses of immunosuppression. 
Experience from Other Centers 
The malignant tumors k-nown to have 
he en observed in renal homograft recipi-
ents in other transplantation centers are 
listed in Table 21. There were 14 carci-
nomas and 13 neoplasms of mesenchymal 
origin. As in our cases, the prognostic im-
plications of the mesenchymal tumors were 
grave and only two of these patients re-
main alive. In contrast, nine of 14 patients 
with carcinomas have been successfully 
treated. 
Discussion 
At the ApriL 1965, meeting of the Ameri-
can Surgical ;\ssociation, an account was 
given of the 36 patients of Series 1 who 
were still alive after follow-ups of one to 
21 ~ years.;" The chronic surviyal of so 
many (.'56%) recipients from an original 
I~roup of 6-l \\'as an encouraging notation, 
particularly since it seemed likelv that the 
majorih' of the homograt'ts \Vere going to 
continue functioning for a long time. Nev-
ertheless. the opinion was offered that ... 
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TABLE 21. J[ alignanl Tumors in Renal H omoKra!e 
.-\ge at 
Time of Thy-
Transplant Trans- Sple- mee- Im- Pred-
No. Center plant Sex Donor neetomy tomy uran nisone ALG 
Minneapolis 16 F Cadaver No No Yes Yes No 
2 Ghent, 53 F Cadaver No No Yes Yes No 
Belgium 
3 Richmond 33 F Sister No No Yes Yes No 
4 San Francisco 46 1\1 a) Son Yes No Yes Yes No 
b) Cadaver 
5 Nashville 3S l\1 Cadaver No No Yes Yes No 
6 Louisville 36 M Brother No No Yes Yes No 
7 Louisville 32 1\1 Brother Yes No Yes Yes No 
8 .Minneapolis 27 ~f Brother Yes No Yes Yes No 
() Xashville 41) ~l Cadaver No No Yes Yes No 
10 ~finneapolis 28 F Brother No No Yes Yes No 
11 :'.[ontreal 38 F Cadaver No No Yes Yes Yes 
12 Los Angeles 27 :'.[ \[other No No Yes Yes No 
13 Los Angeles 25 F Brother No No Yes Yes Xo 
14 Los Angeles 38 F :'.[other No Xo \"es Yes Xo 
IS bdinbur~hI 26 F \!other No Xo Yes Yes Yes 
Scotland 
16 Cleveland No Xo Yes Yes Yes 
• 
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Recipients (Otlter Transplant Centers) 
Time after 
Trans-
Type of Tumor plantation Organs Involved Outcome Ref.· 
Dysgerminoma 32 months Peritoneum; ovary; Fatal Dr. W. Kelly 
mediastinal & axil-
lary lymph nodes 
Adenocarcinoma 35 months Sigmoid colon Alive following ex- Dr. F. Derom 
tensive left hemi-
colectomy 
Squamous cell 36 months Cervix of uterus Cone biopsy. Patient Dr. H. Lee 
carcinoma in being observed at 
situ regular intervals. 
Alveolar cell 9 months Lungs Died Dr. S. Kountz 
carcinoma of 
lung 
Squamous cell 63 months Metastases in lymph Alive following radi- Dr. C. Zukoski 
carcinoma nodes of neck. Pri- cal neck dissection 
mary site of tumor 
unknown 
Squamous cell 8 months Lower lip Alive. No recurrence Dr. D. Leb 
carcinoma after excision. 
Embryonal cell 2 months Testis; abdominal or- Died Dr. D. Leb 
carcinoma gans; ureter of 
transplan ted kidney; 
lung. 
Undifferentiated 10 months Liver; brain; bone Died Dr. C. Hitchcock 
carcinoma marrow 
Undifferentiated I i months Lung; mediastinal Died Dr. C. Zukoski9t 
carcinoma lymph nodes; brain; 
liver 
Squamous cell 30 months Cervix of uterus .\live. No recurrence Or. R. L. Simmons 
carcinoma in after simple 
situ hysterectomv 
Squamous cell 6 months Cervix of uterus Alive. No recurrence Or. K. Pritzker 
carcinoma in following cryo-
situ surgery 
Squamous cell 25 months Lower lip Alive. No recurrence Dr. R. Goldman 
carcinoma after excision. 
Squamous cell 35 months Lower lip Alive. X 0 recurrence Dr. R. Goldman 
carcinoma after excision. 
S'luamous cell K~R months Cervix of uterus: ,\live. XO recurrence Or. :\. Gordon 
carcinoma ill anterior wall of after excision. 
sitll vagina 
Reticulum cell 25 months Lymph nodes; pleura; ratal Prof. :\1. \\"oodrulT·· 
sarcoma spleen; liver; ovary; 
adrenal; bone mar-
row; & transplanted 
kidney 
Reticulum cell 22 months Buttock: frll~pI Fatal Dr. S. D. Ikodhar" 
sarcoma aortic lymph nodes 
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TABLE 21. 
Age at 
Time of Thy-
Transplant Trans- Sple- mee- Im- Pred-
No. Center plant Sex Donor neetomy to my uran nisone ALG 
17 New York 35 F Cadaver No No Yes Yes No 
18 Richmond 35 M Cadaver No No Yes Yes No 
19 Auckland. 34 M Cadaver No No Yes Yes No 
New Zealand 
20 Auckland. 46 F Cadaver No No Yes Yes No 
New Zealand 
21 New York 18 M Uncle No No Yes Yes No 
22 New York 36 M Cadaver No No Yes Yes No 
23 Richmond 29 ~f Brother Yes No Yes Yes No 
H Little Rock. 21 M Father Yes No Yes Yes No 
Arkansas 
25 Boston 34 M a) Cadaver No No Yes Yes No 
b) Half-
sister 
26 :\Iontreal 36 1\1 Cadaver No No Yes Yes No 
27 San Francisco 39 F Sister Yes No Yes Yes No 
• Reported cases annotated; all other cases by personal communication irom the indicated physician or surgeon 
"for the present it would seem most rea-
sonable to regard homotransplantation as 
an effective, but incompletely character-
ized. form of palliative therapy." 
Although 29 (45.3%) of the original 64 
patients in Series 1 remain alive after an 
additional interval of 5 years, there is no 
reason now to change the foregoing point 
of view since late failures have continued 
to be observed. Admittedly, the attrition 
has been slow in the familial cases but the 
delayed loss rate of non-related kidneys or 
their recipients has been excessive. The 
same conclusions are cvident in the late 
reports of other workers in transplantation 
who were active in the 1962-1963 era and 
who now have follow-up data of compa-
rable duration. 2o, 24, 33, 3S, 41, H, 63, 97 
In Series 1 as well as in Series 2 and 3 
of the present report, it is of interest to 
examine the causes of the 24 deaths that 
occurred after 1 year. Since the transplants 
were still providing life su DPorting func-
tion in the maiorit~D of these cases (14 of 
24), it could be tempting to erroneously 
ascribe such failures ('xclusiycly to extra-
renal factors. Examples, C\'en years after 
transplantation, might be fatal myocardial 
infarction, pulmonarv embolization. lym-
phoma. or infection. It is of the utmost im-
portance to appreciate that most of these 
patients who died late had less than nor-
Volume 172 LONG-TERM SURVIVAL AFTER RENAL TRANSPLANTATION 461 Number 3 
(Continued) 
Time after 
Trans-
Type of Tumor plantation Organs Involved Outcome Ref.· 
Visceral Kaposi's 10 months Lungs; esophagus; Fatal Dr. J. H. Siegal'l 
sarcoma stomach; urinary 
bladder; mediastinal 
and abdominal 
lymph nodes. 
Reticulum cell 31 months Lung 
sarcoma 
Reticulum cell 7 months Tongue; esophagus; 
sarcoma liver 
Reticulum cell 9 months Brain 
sarcoma 
Reticulum cell 9 months Brain 
sarcoma 
Reticulum cell 10 months Brain 
sarcoma 
Reticulum cell 67 months Lymph nodes; liver; 
sarcoma vertebrae 
Reticulum cell 24 months Brain 
sarcoma 
Leiomyosarcoma 47 months Stomach 
Leiomyosarcoma 51 months Small bowel; liver; 
pancreas 
Reticulum cell 14 months Brain; lungs 
sarcoma 
mal renal function, that many had hyper-
tension or other complications as a conse-
quence, and that greater than average 
maintenance immunosuppression was usu-
ally being given in order to prevent fur-
ther functional losses. Thus the typical 
late death, whatever its immediate cause, 
tended to occur against a background of 
subnonnal renal function and relatively ex-
cessive immunosuppression. especially with 
steroids. Only two of the patients who died 
after 1:2 postoperative months had excel-
lent homograft function prior to their tcr-
minal illness (Fig. 3). 
If the ahove described delayed deterio-
ration in renal function were due mainly 
to incomplete long-tenn control of the re-
Fatal Dr. J. Pierce 
Fatal Dr. P. Doaku 
Fatal Dr. P. Doak16 
Fatal Dr. R. Porro 
Fatal Dr. F. Veith 
Fatal Dr. H. Lee 
Alive, following Dr. C. Araoz 
radiotherapy 
Alive, receiving local Dr. R. E. Wilsoll 
radiotherapy 
Fatal Dr. L. D. Maclean 
Fatal Dr. F. O. Belzer 
jection process, they should have been pre-
dictable with any system that identified 
major donor-recipient histoincompatibili-
ties. In the present study, the clinical ob-
servations were compared with the widely 
used H A-D antigen match classification. 
\Vith this system, the letters were a state-
ment in code about the compatibility, in-
compatibility or identity of the HL-:\ an-
tigens. 
Following inter-sibling transplantation, it 
was encouraging that histocompatibility 
matching by this method correlated at least 
partially with the outcome. Specifically, the 
designation of an :\ match endowcd a 
,light advantage ill terms of survi,'al ami 
quality of homograft function as \\'l' \I as a 
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highly significant advantage in terms of the 
histopathologic appearance of the kidneys 
at varying times postoperatively. In prac-
tical fact, the designation of an A match in 
sibling cases very often was an indication 
that the donor and the recipient both had 
the same two histocompatibility haplo-
types, one from each parent, and had there-
fore achieved identity of the HL-A anti-
gens; for the HL-A chromosome it could 
be said that there was genotype as well 
as phenotype identity. These observations 
have supported the conclusion from other 
skin or renal transplantation studies within 
families about the relevance of HL-A anti-
gens to histocompatibility.3, s, s, 92 
In contrast, significant clinical or histo-
pathologic correlations could not be dem-
onstrated between the phenotype grades 
and the results with the parent to offspring 
transplantations. With this familial combi-
nation, half of the HL-A antigens of the 
donor (one haplotype) are by definition 
identical to those in the recipient. The re-
maining 50% of HL-A antigens are in es-
sence unrelated. It is the unrelated half of 
the donor-recipient genetic mass which 
finds expression in the A-D score. 
In the parental cases, there could be sev-
eral explanations for the failure to find sig-
nificant relationships between the alpha-
betical grades and survival, function, or 
histopathology. The possibility that the 
HL-A antigens are irrelevant to histocom-
patibility cannot be seriously entertained 
in view of the evidence to the contrary 
cited above in connection with sibling 
cases and in view of the evidence from 
other kinds of studiesKD~· 17, 51 A second pos-
sibility could be that "immunologic arte-
fact" caused by the transmission of pre-
existing host glomerulonephritis to the 
transplants was responsible. However. it 
will be emphasized farther on that the lat-
ter factor alone could not explain all or 
probably eyen the majorit~D of the poor 
correlations. It could also reasonably he 
speculated that: (1) the completeness and/ 
or accuracy with which HL-A phenotypes 
currently can be measured is substantially 
poorer than is generally realized 81; (2) sig-
nificant and presently undetected histocom-
patibility loci existed on other than HL-A 
chromosomes; (3) variable host immuno-
logic reactivity in different patients 21 was 
comparable in importance to the antigen 
match in determining the outcome; (4) or, 
host presensitization to antigens present in 
the homografts 26, 28, 10, 19, 81, 96 jeopardized 
the outcome in a number of instances but 
was not always recognized as a factor. 
In addition, there remains the possibility 
that the A-D system is not an optimal one 
with which to express the real meaning of 
the data obtained by determining indi-
vidual donor and recipient antigens. The 
point of view was emphasized at the Histo-
compatibility Conference held in Los An-
geles in January, 1970.23 Based upon re-
cent progress in understanding the genetics 
of the HL-A system, Rapaport and Daus-
set 58 have proposed that the A-D scale be 
replaced by a numerical index of donor-
recipient histocompatibility called the Net 
Histocompatibility Ratio (NHR). 0 
Whatever the explanation, the experi-
ence with the parental cases reaffirms a 
finding first noted several years ago. In 
many of these same patients as well as in 
mismatched siblings, it was learned 48, 73, 81 
that immuno-suppressive treatment could 
very often override significant or appar-
ently ominous incompatibilities with subse-
quent renal graft survival for many years. 
The durability of related but mismatched 
kidneys has become even more evident 
with the longer follow-ups of 2 to T1~ years 
in the present study. As a consequence. our 
policy continues to be to accept parental 
donors despite the fact that thev may be 
hadly matched. ~foreoverK siblings and 
o In preliminary studies of the cases in the 
present stud~DI Dr. Rapaport believes he has found 
correlations between the )I.; IIR amI the survival of 
recipients of parental and unrelated kidneys as 
well as after inter-sibling transplantation. 
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other relatives are not arbitrarily excluded 
from giving kidneys simply because of an-
tigen incompatibilities, although an effort 
is usually made in this circumstance to de-
termine if the donor and recipient share 
one HL-A haplotype and are therefore ge-
netically similar to a parent-offspring com-
bination (see earlier section "HL-A Geno-
type Correlations" on page 447). If only 
one donor is available, the only absolute 
immunologic contraindication to intrafamil-
ial transplantation in our center is the dem-
onstration of performed antidonor humoral 
antibodies. 
Since the A-D grades failed to conform 
to any identifiable spectrum of outcome 
after the parent to offspring transplanta-
tions, it was hardly surprising to find the 
same lack of correlation within the much 
less fortunate group of patients who re-
ceived non-related kidneys and who tended 
to die or lose their transplants at a higher 
rate both early and late after operation. 
Reducing the risk in this kind of case has 
become one of the great challenges of ap-
plied immunology. It remains to be seen if 
more assiduous application of serologic tis-
sue typing technics will be instrumental in 
improving the outlook of the non-related 
recipient. If so, it now seems' certain, in 
view of the negative results thus far ob-
tained, that improved methods of interpre-
tation must be evolved or else that nearly 
perfect matching of a truly complete set of 
antigens will be required. 
Of course, the foregoing antigenic. clini-
cal, and histopathologic correlations were 
an oversimplification since a significant 
number of early deaths were not immuno-
logic in etiology. Even delayed deteriora-
tion of a renal homograft was not neces-
sarily duc to inadequate control of thc 
rejection process. Three alternative possi-
hilities that wcre always considered in our 
patients \\'('re obstructive uropathy. pyelo-
nephritis. and glomerulonephritis. In the 
cases of the present report. therc were no 
unrelieved high-grade chronic urinary ob-
structions as has been recently documented 
in a separate publication. os Moreover, py-
elonephritis was diagnosed on histopatho-
logic grounds in only two of the 105 homo-
grafts examined 1 or more years after trans-
plantation. 
In contrast, 73 of the 105 specimens 
(70%) examined pathologically 1 or more 
years post-transplantation contained either 
obvious (50 examples) or subtle (23 ex-
amples) glomerular changes of the kind 
caused in experimental glomerulonephritis 
models by antiglomerular basement mem-
brane (anti-GBM) antibodies (Masugi-like 
nephritis) or by the lodgment of soluble 
antigen-antibody complexes in the renal 
microvasculature (complex nephritis). Even 
before a year, these lesions were commonly 
noted, at the earliest after only 2 weeks' 
residence of a transplant in its new host. 
Glomerulonephritis-like lesions have also 
heen noted in renal homografts in a num-
ber of past reports. 11, 21, 32, P~I 30, 31, 40, n, H, 
:13, :51 
Tabulation of such a high incidence of 
glomerular abnormalities has made it de-
sirable to try to determine whether they 
are a manifestation of humoral antibody 
rejection or a continuation of pre-existing 
glomeruloncphritis. The criteria of the dif-
ferentiation have been necessarily vague 
since. as McPhaul and Dixon have pOinted 
out,39 analogous nephritogenic mechanisms 
could be responsible under hoth circum-
stances, differing primarily in the nature of 
the antigen. 
The circumstantial evidcnce from the 
present study has suggested that a com-
mon and possibly thc predominant cause 
of glomerulonephritis in transplantcd kid-
neys was indolent rcjection. For one thing, 
glomerulonephritis d('vclopcd in the homo-
grafts of several patit'nts whosc original re-
Ilal diseasc did not have an allto-immunc 
etiology. Another ohservation in sllpport of 
the rejection pathogenesis was that the in-
ddence of ohvious glomcrulonephritis was 
less with good histocompatibility as in 
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double haplotype identical siblings. Con-
versely, the incidence was exceedingly high 
in the generally less well matched non-
related kidneys. 
However, there were also strong indica-
tions that many renal homografts were ad-
versely affected by "transmission" of the 
disorder which had made transplantation 
necessary in the first place. If the original 
host disease was glomerulonephritis, the 
chance of having such a diagnosis made in 
the transplant was greatly increased. More-
over, 23 (22%) of the 105 homografts ex-
amined a year or more after operation had 
glomerulonephritic lesions that were strik-
ingly similar or absolutely indistinguish-
able from those in the native kidneys. These 
observations of "transmission glomerulone-
phritis" support the opinions expressed by 
McPhaul and Dixon and their associates 39 
but are at variance with the interpretations 
of Merrill,.o Najarian and Foker;5 and Wil-
liams, Lee and Hume. u5 Although the exact 
incidence of "rejection" as opposed to 
"transmission" glomerulonephritis is not 
known, it is obvious that the immunosup-
pressive technics used thus far do not con-
sistently prevent this complication. 
Only two programs of immunosuppres-
sive therapy have been thoroughly tested 
in humans. The first, which was introduced 
in 1962 and 1963, e5. 43, I~K D8 consisted of 
double drug therapy with azathioprine and 
prednisone. With the other regimen, het-
erologous antilymphocyte globulin (ALG) 
was added to these h\'o agents in a triple 
drug combination, usually confining the 
globulin treatment to the first 4 postopera-
tive months. In our center, the death and 
kidney loss rates fell sharply after June 
1966 when ALG was introduced. tlO , 71. ,11 
5imilar clinical trials have heen reported 
with ALG in other institutions. \ Vith one 
exception,5S the experience with the triple 
drug treatment has been reported as fa-
"orable I, Ii, 30, 5<. GO, ". >5-00 with a reduced 
mortality allli/or hetter homograft func-
tion. 
In the present study, the magnitude of 
tissue injury at about 2 years has been 
added to survival and function as a third 
measure of the effectiveness of treatment. 
Although the patients reached this level of 
convalescence more consistently than in 
the past, the grafts under treatment with 
triple drug therapy were in no better con-
dition than kidneys sampled at compa-
rable times in the double agent era. The 
findings are not different from those re-
ported from our earlier experience with the 
triple drug treatment.76 
In addition to the effects of various im-
munosuppressive agents, there may be a 
slowly evolving attenuation of host immu-
nologic responsiveness as a consequence of 
recipient thymectomy. In a recent full re-
port·~ of the human thymectomy experi-
ence that was brieHy summarized in the 
present communication, the evidence was 
reviewed from animal experimentation that 
predicted an effect in adult humans. De-
spite this expectation, there did not seem to 
be any inHuence at all upon either surviv~l 
or homograft function in our patients who 
were submitted to this adjuvant procedure. 
However, the homo grafts transplanted to 
the recipients with absent thymus glands 
developed significantly fewer and less se-
vere abnormalities. 7 ;; In no sense can this 
latter observation be construed as a recom-
mendation that thymectomy be included as 
part of the standard preparation for trans-
plantation. Yet it has reopened the ques-
tion of conducting further well controlled 
studies to clarify the issue of thymectomy 
in humans. 
It is probable that a final judgment about 
the value of organ transplantation will de-
pend upon more knowledge of the liabili-
ties associated with chronic immunosup-
pression. It has been proved that patients 
l'an live in good health for many years pro-
\"iding they can maintain function of their 
transplants without the need for excessive 
drug doses. In such recipients, there has 
not been an alarming tendency for the de-
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velopment of life threatening late infection. 
A more serious long-term risk may be that 
of malignancy. The findings in the present 
report reinforce previous warnings 15, 50-52, 
65, 61 that an increased incidence of neo-
plasia may be one of the more serious ulti-
mate limitations in the application of trans-
plantation procedures for the treatment of 
human disease. 
Summary 
Kidney transplantation was performed 
for 189 victims of renal failure during 3 
periods: 1962-1964 (Series 1), 1964-1966 
(Series 2), and after June 1966 (Series 3). 
The patients of Series 1 and 2 were treated 
with azathioprine and prednisone; despite 
the acquisition of a large experience dur-
ing this 4-year interval, the mortality re-
mained relatively fixed. In Series 3, horse 
ALC was also given, usually for the first 4 
postoperative months. This change was as-
sociated with an improvement in survival 
but not with any definite quantitative or 
qualitative changes in the histopathology 
of the chronically functioning homografts. 
Seventy nine of the 189 patients have died. 
The causes of early as well as late mor-
tality in all three series were usually asso-
ciated with toxicity from immunosuppres-
sive therapy, with failure of the immuno-
suppression to completely control rejection, 
or most commonly to a combination of 
both factors. 
In all three eras of our experience, the 
majority of the recipients of related kid-
neys derived long lasting benefits with one-
year survival rates in Series 1, 2, and 3 of 
67%, 68, and 92%, respectively. With fol-
low-ups of 2 to 71h years in these familial 
cases, 91 of the 131 consecutive patients 
(69.5%) are living and 88 (67.270) of the 
originally transplanted homografts are still 
functioning. The type of consanguinity was 
1I0t a critical factor in determining thl' out-
come since thl' l-year. ;2-\'l'ar and current 
survi,'al \\'as approximately the same \\'ith 
the use of organs from siblings, parents and 
more distant relatives. 
With non-related donors (both volunteer 
and cadaveric) the salvage of life and the 
degree of social and vocational rehabilita-
tion were less gratifying. When Series 1 
was compiled in 1962 and 1963, two thirds 
of the recipients of non-related kidneys 
( 12/18) died within the first postoperative 
year. In Series 2, the one year mortality 
dropped to 48% (11/23) whereas in Se-
ries 3 only 17.7% (3/17) failed to live for 
at least 12 months with life-supporting 
function of the transplant. In all three se-
ries, late failure of unrelated homo grafts 
(after a year) was far more common than 
with the familial kidneys. Consequently, 
only 19 (33ro) of the 58 patients treated 
1 to 7 years ago are still surviving, and in 
three of these 19 cases by virtue of retrans-
plantation. 
In most of the cases, typing of the HL-A 
antigens of both the donors and recipients 
was carried out with a lymphocytotoxicity 
test. From these measures, matches of the 
antigen phenotypes were designated on a 
scale of A to D. After inter-sibling trans-
plantation, the recipients of A-matched kid-
neys had better average renal function and 
an increased long-term survival. In addi-
tion the incidence and severity of histo-
pathologic abnormalities in the matched 
transplants were minimal. It was shown by 
genetic analysis that these favored grafts 
tended to have been given by donors who 
had double haplotype identity of the HL-A 
chromosome with the recipients. 
With parent to offspring transplantation 
or with transplantation between more dis-
tant relatives or non-related people, no cor-
relation existed between the A-D phenotype 
matching grades versus survival, function 
and histopathology. Several explanations 
for these negative findings were discussed, 
including the possibility that the A-D scor-
ing was not an optimal way of converting 
the raw typing data to an expression of the 
quality of HL-A compatibility. 
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The possible role of glomerulonephritis 
in obscuring histocompatibility correlations 
was evaluated and found to be a factor of 
potential, though probably not overriding 
significance. There were 105 renal homo-
grafts examined one year or more after op-
eration. By light microscopic examination 
50 (47.6%) had one variety or other of glo-
merulonephritis. Another 23 transplanted 
kidneys (21.9%), without obvious glomeru-
lar abnormalities by light microscopy, had 
more subtle findings detectable by ultra-
structural or immuno-fluorescence exami-
nation. Evidence was presented that the 
most common cause of homograft glo-
merulonephritis was slow rejection medi-
ated primarily by humoral antibodies. In 
support of this contention were the facts 
that: (1) the diagnosis of homograft glo-
merulonephritis was made in some cases 
in which the original host disease had not 
been of autoimmune etiology; (2) good 
histocompatibility matching (as in the dou-
ble haplotype identical siblings) was asso-
ciated with a decreased rate of glomerulo-
nephritis; (3) histoincompatibility predis-
posed to glomerulonephritis as shown by 
the higher incidence in unrelated as op-
posed to related cases. On the other hand, 
there were many patients in whom the 
transplanted organs apparently were ad-
versely affected by continuation of the 
same disease that had destroyed the native 
kidneys. The evidence favoring this se-
quence of events was that: (1) The inci-
dence of glomerulonephritis in the trans-
plants was higher if this was the original 
diagnosis; (2) glomerular changes in the 
grafts \\'ere very often (23 well documented 
examples) a faithful or nearly faithful ana-
tomic recapitulation of the disease that had 
necessitated transplantation in the first 
place. 
qhvmectom~D as an adjuvant immunosup-
pressive measure was {'valuated in a group 
of 46 patients treated from 4 to .'5 1 ~ years 
ago. Before transplantation the thymus 
gland "'as removed transthoracically in 24 
randomly selected recipients whose s1\bse-
q uent fate was compared to that of the 22 
others who did not have thymectomy. The 
patients with thymic excision did not have 
better survival or superior renal function, 
but their homografts tended to have fewer 
and less severe histopathologic abnormali-
ties when examined long after transplanta-
tion. 
Ten (5.3%) of the 189 patients in the 
present report have developed carcinomas 
(seven examples) or mesenchymal malig-
nancies (three examples). In addition, 27 
cases of de novo malignancy have been 
collected from other institutions and sum-
marized. From the data, it was concluded 
that an increased risk of neoplasia is yet 
another penalty for chronic iatrogenic im-
munosuppression and that the complica-
tion is not related to the use of any indi-
vidual agent. In our recipients, eight of the 
10 malignancies were cured by conven-
tional forms of treatment; the other two 
died of widespread reticulum cell sarcoma. 
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DISCUSSION 
DR. THOMAS C. MOORE (Los Angeles): Two 
years ago Dr. David Hume and I carried out an 
indepth review of the Richmond experience with 
first kidney transplants. The results of this study 
have been published as three articles in the July 
1969 issue of Annals of Surgery. All but a handful 
of these patients had been followed from 1 to 6lf 
years following transplantation. 
At the time of our review 49 of 75 related 
living donor (RLD) recipients were living with 
functioning transplants. The initial and continuing 
level.of function as mirrored in BUN and creati-
nine levels was considered to be of considerable 
prognostic importance. 
in the two years since our review, eight of 
these 49 functioning RLD transplants have been 
lost; four due to patient dcath and four as a re-
sult of transplant failure lead to nephrectomy. 
Three of the deaths involved patients with ex-
cellent transplant function Sl~ to 7 vears after 
transplantation (all had creatinines in the 1.0 
range). Two died of malignancy (one of leukemia 
and one of lymphom[1) and one was suspected 
suicide. The other dCGth resulted from liver fGil-
ure 4 yeGrs post-transplant. One additional patient 
is living in a tenuous wav with severe liver dam-
age which recently required portocaval shunting 
for portal hypertension and blceding varices. Three 
of the four transplants lost duc to transplant fail-
ure and nephrectomy were in trouble at the time 
of the last report. The other trnnsplant which 
failed had functioned at [1n intermediate level Gntl 
failed during a period of serious pulmonary infec-
tion. 
Twenty-four living RLD patients continuc. 
three to T!~ years post-transplant. to have the ex-
cellent level of function of 20 BLT:'\-1.2 crcatinine 
or better. :\'one of the patients who had this le"el 
of function 2 years ago have slIlfered any deteri-
oration of function in the interval since our last 
report. Seven additional patients helve creatinines 
(Cr) in the 1.3-1.3 range. The patient whose 
function deteriorated modcrately dming pregnanc" 
but recovered in the initial 8 months post-partum. 
currently has a BU:--I of 11) and a Cr of 1.0 .'5!; 
years after transplantation. and the surviving C-
match \Vihn's tumor patient has a BU:\, of 19 and 
a Cr of 1.0 six years after transplantation. 
diation and Postoperative Administration of 
an Antimetabolite (Imuran). Lancet, 2:675, 
1963. 
99. Zukoski, C. F., Simmons, J. L., Killen, D. H., 
Ginn, E., Matter, B., Lucas, D., Seigler, H. 
and Crews, D.: Cancer in Patients on Im-
munosuppressive Therapy. Transplanted and 
Spontaneous. JAMA, 204:537, 1968. 
With a recent BUN of 18 and a Cr of 0.9, 
the patient who was given Isoniazid (isonicotinic 
acid hydrazide) during first and second transplants 
for tuberculosis continues to survive with a func-
tioning transplant 53 months after receiving a CD 
second transplant. 
At the time of our study, 2 years ago, 15 first 
transplant cadaver donor (CD) recipients had 
functioning transplants. One of these kidneys still 
are functioning. Four kidneys have been lost due 
to patient death, all at comparatively short-term 
risk, and one from failure and transplant nephrec-
tomy. Of the ten functioning CD kidneys cur-
rently at risk from 2)' to 6 years, nine have creati-
nines of 1.6 or better. Of the nine CD kidneys at 
risk more than 2 years at the time of our study 
:2 years ago, only one kidney and no patients have 
been lost and scven of the eight surviving kidneys 
are functioning at a surprisingly satisfactory level. 
:--lone of thcse scven have shown any significant 
deterioration in function in the past :2 years and 
all are in the 4- to 6-year range post-transplant. 
One patient .'i Y('ars and 9 months post-transplant 
has a BUN ot 23 and a Cr of 1.3 and one .5 years 
ell1d 1 month has a BUN of 17 and a Cr of 1.1. 
This is a very cncouraging finding for CD re-
cipients at risk 2 and more years and with reason-
ably adequatc function. From a group of 20 con-
secutive CD first transplants at risk from 4 to (J 
years, eight (40%) continue to function. 
In the :2 years since our study, two new haz-
ards in long-term survivors have risen: the threat 
of reticuloendothelial and hone marrow types of 
malignancy and the hazard of liver failure from 
chronic hepatic injnry. Both of these late hazards 
probably arc related to long-term azathioprine ad-
ministration. Because of these findings, \H' mllst 
Llise the qllestion of the fe[1sahilitv and desirabil-
ity of substantial. gradual reductio~ in azathioprine 
administration in long-knn survivals. Other agents 
including dmgs stich as the antihistamines and iso-
nicotinic acid hydr[1zidc \\.,' are using :tt UCLA 
might be lltilized to facilitate redllction or elimi-
lIation of azathioprine adlllinistration in the period 
I fter 2 or 3 y('ars. 
Dr. Starzl has mentioncd their cspcriencc with 
'pontancolls malignanc\'. I wOllld like to G,k him 
.lhollt their problcllls with hepatic (\.tmage in long-
tenn survivors. 
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DR. RICHARD E. Wn.SON (Boston): I would 
like to try and supplement Dr. Stam's data with 
findings from our transplant program at Peter Bent 
Brigham Hospital. I think this will enable the 
members and guests to arrive at a consensus which 
is important at this stage in the management of 
patients with renal and other transplants. 
I wish to discuss three aspects of his presenta-
tion. One of the typing, the second is the use of 
antileukocyte globulin and the third is the prob-
lem of the late rejecting kidney, or glomerulone-
phritis. 
We have cooperated with Dr. Teraski as has 
he, since the onset of his typing work, and have 
had all of our patients typed in Los Angeles, as 
well as their being typed locally in Boston. We 
have never rejected a patient because of a poor 
match except when they were presensitized, 
Teraski-"F" match. 
Our living donors with an A match have done 
very well, but our living donors with B matches 
have not done any better than C or D matches; 
in fact many were worse. Some of them have had 
very early rejections and I am sure, as Dr. Stanl 
mentioned, this probably represents a fault in the 
sophistication of typing more than anything else. 
Our cadaver donor kidneys have done equally 
well, B, C and D matches and, again, if anything 
the C and D matches have done better than the 
B's. 
Our philosophy about this typing program is 
much as that which Dr. Stanl summarized: that 
is, we believe we must continue to type, that we 
must become more sophisticated but we certainly 
do not believe that at the moment we have all of 
the antigens properly matched, nor can we for 
any given patient predict the exact outcome of a 
given kidney. 
In regard to antileukocyte globulin, about Og~ 
years ago we hegan using antileukocyte globulin 
in a controlled study with alternate living donor 
and mdaver donor patients receiving ALC and 
the other half not receiving ALC. To this date, 
we have about 80 patients with about 20 in each 
of the four groups. 'Ve cannot find any difference 
in survival at 3 months and at 1 year in these 
patients and the only thing that appears to be 
better in the ALC treated patients is less severe 
and probably fewer rejections. This is much more 
subjective difference. \Ve arc continuing to work 
,It this with hopes that better ALC and better 
ways of using it may make it more effective for 
immunosuppression in patients. All of this has been 
subcutaneollslv administcred. 
Finally, w'e would agree completely with Dr. 
Starzl\ points about late rejection and failure to 
he ahle to reallv differentiate this from chronic 
~fomerlll!llllDphritisK The changes in these late kid· 
nevs :lre certainl\' ~EDyDereI v:1scnlar in ll:1ture and 
;1f;~ the end remit of imlllunologic damage, be it 
~lElmertllonephritis or transplant rejection. 
Dn. I).WIIl ~1K IIu:\!E (Richmond): I would 
certainlv Ill' willing to accept that Dr. Starzl's fig-
ures seem to indicate that ALC has improved his 
results, particularly in the unrelated donor groups. 
However, I would like to sound a word of caution 
about the ready acceptance of this conclusion. It 
is unwise to judge the results of organ transplanta-
tion, particularly from cadaver donors, until at 
least 2 years have gone by. It is gratifying that 
this is now the case for Dr. Stam's series, but the 
results without ALS in our own series at this time 
interval are comparable to those he just presented. 
The most recent group related living donor trans-
plants had a functional survival at 1 year of 92%, 
and n survival to P~ years of 80%. This is sur-
vival of functioning grafts, not just patient sur-
vival, which is, of course, better. 
In the cadaver donor group, the 1 year sur-
vival of 19 consecutive recent cadaver donor trans-
plants was 95%, while the 2- to 4-year survival 
was 53%. These figures do not greatly differ from 
Dr. Starzl's with ALC, and illustrate the difficulty 
in comparing recent results with past results as a 
consequence of the over-all improvement in the 
handling of the patient, apart from the addition of 
ALG. 
All ALC's are certainly not the same, and it 
may well be that the difference between Dr. Wil-
son's results and Dr. Stanl's relate to the ALC 
itself. ALG is assuredly a tremendously important 
tool in transplantation, but the details of its pro-
duction, assay, and utilization still remain to be 
clarified and standardized. 
The second comment I would like to make re-
lates to the incidence of recurrent nephritis. In 
our own series, the incidence has been very much 
less than the 22% reported by Dr. Stanl. We 
have had only two instances of definite recurrent 
nephritis in which the disease in the transplant 
was identical in every respect to the disease in 
the original host kidneys. In two additional in-
stances the host developed nephritis in the trans-
planted kidney of a type different from that in his 
own kidneys. A fifth patient developed anti CBM 
nephritis in the transplant, but had no known dis-
ease in his own kidneys prior to the development 
of cortical necrosis after :m accident. 
We have noted many instances in which the 
transplanted kidney has developed chronic rejec-
tion nephritis, and there appear to be at lcast three 
circumstances which predispose to its appearance. 
Thc first is in children who had nephritis in their 
own kidneys. who arc mll(.:h more apt to develop 
proteinuria in the transplant than adnlts. The sec-
ond arc those A-matchcd related living donors 
who had glomerulonephritis. of whom :32% have 
had the nephrotic syndrome in the tr~msplantK The 
third group arc the poorly matched patients, 
whether or not they oril!inally had glomerulone-
phritis. The poorly matehed related living donors 
had a 65% incidence of proteinuria, while the 
poorly matched cada\'<'f donors had a 90% in-
cidence. I should like to ask Dr. Starzl if he has 
noted sinlilar nmlings? 
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DR. THOMAS E. STARZL (Closing): I will try 
to respond to one or two of the issues that were 
raised by each of the three gentlemen. 
Dr. Moore, Dr. Israel Penn did a formal study 
on the incidence of liver disease in our renal 
transplant patients (Current Topics in Surgical 
Research, I: 67, 1969) and found a significant in-
cidence of liver disorders at all times postopera-
tively. Over-all, more than half the patients had 
abnormal liver function tests at some time. The 
evidence of hepatic injury ranged from minor rises 
in SGOT all the way to death from liver failure. 
The time of greatest risk was early postopera-
tively. However, we also had two late deaths from 
liver failure of exactly the kind that you men-
tioned. These fatalities were after 18 and 25 
months. 
I agree in principle with everything that Dr. 
Wilson said, including the need for improved tis-
sue typing. However, it does not seem likely that 
the mere discovery of new antigens will really 
help us to improve practical typing. Rather, 
longer lists of antigens could make the whole 
problem more unmanageable than it already is if 
the major objective is to match up these increas-
ingly numerous phenotypes. At the 1970 Histo-
compatibility Conference in Los Angeles, one of 
the main items of discussion was the means by 
which the phenotypes could be used to establish 
more meaningful genotypes even when matching 
between unrelated people. This approach fomls 
the basis for the formulae of Rapaport and Dausset 
that are discussed in the tcxt. The outcome of 
such studies may ultimately lead to Simplification 
of matching of fewer rather than more antigenic 
determinants. 
I would also agree with much of what Dr. 
Hume said inclmling the desirability of controlled 
clinical studies in which some patients receive 
ALG while other comparable controls do not. Be-
cause we are convinced of the value of ALG, we 
cannot in good conscience perform such studies 
which will have to be left to those who are more 
skeptical. We feel approximately the same way 
about ALG for hepatic and cardiac transplantation. 
As to the factors that underlie transplant glo-
merulonephritis, Dr. Hume's main point was one 
that we would very definitely agree with, namely 
that bad histocompatibility predisposes to this 
complication. The best way to support the con-
tention is to point out that recipients of nonre-
lated kidneys have an incidence of graft glomeru-
lonephritis that is greater than that in recipients of 
related kidneys. By definition, the nonrelated cases 
should have a higher average rate of histoincom-
patibility whether you can accurately measure it 
or not. Moreover, familial kidneys that are known 
to be exceptionally well matched (because they 
come from double haplotype identical sibling do-
nors) tend to have the lowest incidence of glomer-
ulonephritis of any subgroup of cases. Of course, 
these observations are circumstantial evidence that 
glomerulonephritis Can be a manifestation of graft 
rejection. In the text, evidence will also be con-
sidered of the alternative possibility that trans-
plant glomerulonephritis may be a continuation of 
the original host disease that necessitated trans-
plantation in the first place. In our opinion, both 
mechanisms playa role. 
The question about the incidence of glomerulo-
nephritis in children is une that we are looking at 
at the present time. I do not have the data or-
ganized with which to answer the question accu-
rately at this time. In a general way I can say 
that since we have seen "transmission glomerulo-
nephritis" in all age groups we do not consider it 
a unique risk of pediatric recipients. 
